SD Biosensor, Inc.

As of June 30, 2026, SD Biosensor, Inc. carries a market capitalization of 763.17B, placing it among publicly traded companies globally. Its enterprise value stands at 604.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

SD Biosensor, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, SD Biosensor, Inc. has 119.62M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.03, and the price-to-book ratio stands at 0.32.

As of June 30, 2026, SD Biosensor, Inc. trades at an EV/EBITDA multiple of 9.90 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.82 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 604.70B versus a market cap of 763.17B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, SD Biosensor, Inc. maintains a current ratio of 6.51, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.85, indicating elevated leverage, while an interest coverage ratio of 0.67 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SD Biosensor, Inc. posted a negative return on equity (ROE) of -26.91, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -21.38, reflecting losses generated across the asset base. The company generates approximately 1.14B in revenue per employee across its workforce of 645.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.61 indicates how many times SD Biosensor, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, SD Biosensor, Inc. recorded an income tax benefit of -63.58B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -794.66B and -729.49B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, SD Biosensor, Inc.'s stock has declined approximately 30.53% over the past 52 weeks. The 50-day moving average sits at 6,334.20, while the 200-day moving average is 7,407.95.

Over the twelve months ended June 30, 2026, SD Biosensor, Inc. generated 738.76B in revenue and converted that into -729.49B in net income, yielding earnings per share of -6,107.14. EBITDA reached 61.07B, while operating income came in at -64.66B.

As of June 30, 2026, SD Biosensor, Inc. holds 449.51B in cash and equivalents against 285.11B in total debt, resulting in a net debt position of 38.20B. Total book value stands at 2.40T, with working capital of 773.01B providing operational flexibility.

SD Biosensor, Inc. produced 56.74B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -46.02B in capital expenditures, free cash flow totaled 10.72B - equivalent to 89.55 per share.

Over the twelve months ended June 30, 2026, SD Biosensor, Inc. posted a gross margin of 46.83, reflecting its pricing power and cost economics. The operating margin of -8.75 and net profit margin of -98.75 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, SD Biosensor, Inc. paid dividends of 0.40 per share. The dividend payout ratio of -0.01 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 1.40, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 58.08, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to SD Biosensor, Inc. shareholders.

As of June 30, 2026, SD Biosensor, Inc. has an Altman Z-Score of 3.06, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.